New advisors bring decades of industry drug discovery leadership and foundational scientific expertise across Proxima's proximity therapeutics engine and structural proteomics data platform
Proxima, a frontier AI company specializing in proximity therapeutics, appoints three scientists to its Scientific Advisory Board. Dr. Raymond Deshaies, Dr. Lyn Jones, and Dr. Juri Rappsilber join to guide research in AI-driven drug discovery. The company leverages AI to generate novel data for next-generation medical treatments.
Proxima, an AI-native biotech company, secures an $80 million seed round led by DCVC to advance AI-driven drug discovery for proximity-based therapies. The financing includes participation from NVIDIA’s venture arm NVentures, Braidwell, Roivant, and other strategic investors. The company previously operated as VantAI and focuses on developing proximity therapeutics using AI-driven approaches.
